Drug Delivery Systems Market to Hit USD 63.38 Billion by 2032; Rising Prevalence of Chronic Ailments to Bolster Market Expansion

The drug delivery systems market size was valued at USD 42.71 billion in 2023 and is predicted to reach USD 46.23 billion in 2024. The market is anticipated to touch USD 63.38 billion by 2032, recording a CAGR of 4.0% over 2024-2032.

Fortune Business Insights™ presents this information in its latest report titled “Drug Delivery Systems Market Size, Share & Industry Analysis, By Type (Inhalation, Transdermal, Injectable, and Others), By Device Type (Conventional and Advanced), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Regional Forecast, 2024-2032”.

A drug delivery system is a mechanism designed to administer medicines in the body to enhance their efficacy and safety. This is achieved by regulating the dosage form, timing, and site of release. These systems encompass jet injectors, auto injectors, and syringes and are distributed to pharmaceutical companies and end-users through hospital pharmacies, retail pharmacies, and online pharmacies. Market participants are implementing strategies comprising new product launches and collaborations, thereby contributing to the growth of the drug delivery market in the future.

The COVID-19 pandemic resulted in a slowdown of the market in 2020 due to reduced hospital admissions, disturbances in supply chain, temporary manufacturing suspensions, and other global factors. A resurgence is anticipated post-pandemic, driven by an increase in hospital visits and the introduction of advanced drug delivery systems.

Innovation Zed Received CE Mark for its InsulCheck DOSE

Innovation Zed, a prominent key player, received the CE mark for its InsulCheck DOSE. This dose is a single-unit add-on device, particularly for insulin pen injectors.  It automatically collects injection event time stamps, temperature, and mounting and unmounting events and then sends them to a compatible display device.

Increasing Incidence of Chronic Ailments to Propel Market Growth

The increasing incidence of chronic diseases and emergence of new technologies to treat them are the key factors driving the drug delivery systems market growth. According to the United Health Foundation, in 2022, approximately 56 million adults in the U.S. were aged 65 years and above. Such a large group of people being susceptible to chronic diseases is projected to increase the usage of these systems. Additionally, increase in the introduction of new products and digitalization in the healthcare industry have created significant growth opportunities for the market players.

However, the stringent regulations associated with the approval of these products and their invasive nature could impact customers' trust in the devices, impeding the market’s progress.

Leading Players to Focus on Expanding Production Capacity to Expand Their Market Share

Some of the leading players operating in this market include Nemera, Medtronic, Ypsomed, and E3D Elcam Drug Delivery Devices. These companies are focusing on introducing advanced products and expanding production capacity to cater to the growing demand for drug delivery services and expand their market share.

Notable Industry Development:

• March 2022: Vitaris, Inc., in collaboration with Kindeva Drug Delivery L.P., obtained approval from the U.S. FDA for Breyna, an inhalation aerosol combination for patients with asthma and COPD.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/drug-delivery-systems-market-103070

List of the Companies Profiled in the Report:

• Gerresheimer AG (Germany)


• BD (Becton, Dickinson and Company) (U.S.)


• Kindeva Drug Delivery (U.S.)


• Baxter (U.S.)


• West Pharmaceutical Services Inc. (U.S.)


• Ypsomed (Switzerland)


• Medtronic (Ireland)


• Nemara (France)


• E3D Elcam Drug Delivery Devices (Israel)

Further Report Findings:

• North America is anticipated to dominate the global drug delivery systems market share during the forecast period. The increasing demand for advanced drug delivery systems, such as metered-dose inhalers and sensor-embedded devices and increasing prevalence of chronic diseases are expected to fuel the region’s growth.


• Europe accounted for the second-leading position in 2023 and is anticipated to record a significant CAGR during the forecast period. This growth can be attributed to the increasing number of clinical trials to receive key regulatory approvals for novel products and launch of novel products by leading market players in the region.


• Base on type, the injectable segment accounted for the largest drug delivery systems market share in 2023 and is anticipated to maintain its dominance during the forecast period. The rise in the number of vaccination drives globally is fueling the demand for syringes.

Table of Segmentation